ConvaTec, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on the stock and has a p315.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Christian Glennie has given his Buy rating due to a combination of factors including ConvaTec’s consistent organic revenue growth and alignment with its financial guidance. The company reported a 6.3% organic revenue growth for the first ten months of 2025, which is in line with its FY25 guidance and reflects strong performance across all divisions. Additionally, the company has maintained its guidance for an adjusted operating profit margin of 22.0-22.5% and expects double-digit growth in adjusted EPS, reinforcing its financial stability.
Furthermore, the initial outlook for FY26 suggests continued growth with expectations of 5.0-7.0% organic growth and further expansion in operating margins. Despite some challenges, such as the impact of tariffs, ConvaTec remains on track to achieve its near-term targets. Glennie believes that the perceived risks are overstated, which supports the reiteration of the Buy rating.
According to TipRanks, Glennie is a 2-star analyst with an average return of 1.6% and a 32.93% success rate. Glennie covers the Healthcare sector, focusing on stocks such as EKF Diagnostics Holdings, Genus plc, and ConvaTec.
In another report released on November 7, UBS also reiterated a Buy rating on the stock with a p375.00 price target.